Elder, MA
Allison Elder, North Adams, MA US
Patent application number | Description | Published |
---|---|---|
20120171132 | COMPOSITION CONTAINING AN ALKOXYSILANE AND HYALURONIC ACID - A composition comprising: at least one alkoxysilane having at least one solubilizing functional group and at least one amino substituent; at least one glycosaminoglycan chosen from hyaluronic acid; water; optionally, at least one auxiliary ingredient; and optionally, at least one volatile solvent. | 07-05-2012 |
20130280196 | COMPOSITION CONTAINING AN ALKOXYSILANE AND HYALURONIC ACID - A composition comprising: at least one alkoxysilane having at least one solubilizing functional group and at least one amino substituent; at least one glycosaminoglycan chosen from hyaluronic acid; water; optionally, at least one auxiliary ingredient; and optionally, at least one volatile solvent. | 10-24-2013 |
Amy Elder, Arlington, MA US
Patent application number | Description | Published |
---|---|---|
20100179126 | THIOLACTAMS AND USES THEREOF - This invention provides compounds of formula I: | 07-15-2010 |
20110144090 | COMPOUNDS AND METHODS OF USE THEREOF - Indole compounds are disclosed. Also disclosed are methods for using the compounds to treat human and animal disease, pharmaceutical compositions of the compounds, and kits including the compounds. | 06-16-2011 |
20110257157 | THIOLACTAMS AND USES THEREOF - This invention provides compounds of formula I: | 10-20-2011 |
20120302551 | THIOLACTAMS AND USES THEREOF - This invention provides compounds of formula I: | 11-29-2012 |
20120309743 | THIOLACTAMS AND USES THEREOF - This invention provides compounds of formula I: | 12-06-2012 |
20130053341 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE - Methods of treating disorders using compounds that modulate striatal-enriched tyrosine phosphatase (STEP) are de-scribed herein. Exemplary disorders include schizophrenia and cognitive deficit. | 02-28-2013 |
20140315886 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE - Methods of treating disorders using compounds (I) that modulate stri-atal-enriched tyrosine phosphatase (STEP) are described herein. Exemplary disorders include schizophrenia and cognitive deficit. Formula (I). | 10-23-2014 |
Amy M. Elder, Arlington, MA US
Patent application number | Description | Published |
---|---|---|
20090163497 | Compounds Useful as Antagonists of CCR2 - The present invention provides compounds of general formula (I) or a pharmaceutically acceptable salt thereof, wherein X, n, Y, and R | 06-25-2009 |
20090181966 | PGD2 receptor antagonists for the treatment of inflammatory diseases - Disclosed herein are compounds represented by Structural Formula (I) and (I-A): | 07-16-2009 |
20090197884 | Compounds Useful as Antagonists of CCR2 - The present invention provides compounds of general formula I: or a pharmaceutically acceptable salt thereof, wherein X, n, Y, and R1 are defined generally and in subsets herein. Compounds of the invention are inhibitors of CCR2 and accordingly are useful for the treatment of a variety of inflammatory, allergic, and autoimmune diseases, disorders, or conditions. | 08-06-2009 |
20090281081 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR - Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: | 11-12-2009 |
20100016289 | Compounds Useful as Antagonists of CCR2 - The present invention provides compounds of general formula I: (I) or a pharmaceutically acceptable salt thereof, wherein X, n, Y, and R | 01-21-2010 |
20120046311 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF - Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: | 02-23-2012 |
20120208818 | COMPOUNDS USEFUL AS ANTAGONISTS OF CCR2 - The present invention provides compounds of general formula I: | 08-16-2012 |
20120214807 | COMPOUNDS USEFUL AS ANTAGONISTS OF CCR2 - The present invention provides compounds of general formula I: | 08-23-2012 |
20140194410 | THIOLACTAMS AND USES THEREOF - This invention provides compounds of formula I: | 07-10-2014 |
20140371207 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF - Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: | 12-18-2014 |
Bruce J. Elder, Andover, MA US
Patricia Elder, Florence, MA US
Patent application number | Description | Published |
---|---|---|
20090216555 | SYSTEM, METHOD AND COMPUTER PROGRAM PRODUCT FOR PERFORMING AUTOMATIC SURVEILLANCE AND TRACKING OF ADVERSE EVENTS - A system, method and computer program product are provided for automatically detecting and tracking adverse events. The system may include one or more data sources configured to provide a combination of clinical, operational and financial data associated with each of a plurality of patients. The system may further include a network entity configured to receive at least part of the combination of data and to apply one or more trigger rules to the combinations of data to identify one or more suspected adverse events. The network entity may further be configured to receive an indication of one or more confirmed adverse events from among the suspected adverse events, and to automatically compile at least part of the combination of data associated with respective patients in association with which the confirmed adverse events occurred. The system may further include a user device configured to enable performance of a root cause analysis of the compiled data. | 08-27-2009 |